Alfonso Salvatore

Dr. Alfonso Salvatore

Kedrion Biopharma
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2007 in Biochemistry
Verified
Journal Article
Closed access
Alfonso SalvatoreAlfonso Salvatore
Alfonso Salvatore
LCLuisa Cigliano
Luisa Cigliano
EBEnrico M. Bucci
Enrico M. Bucci
DCDavide Corpillo
Davide Corpillo
SVSilvia Velasco
Silvia Velasco
PAPaolo Abrescia
Paolo Abrescia

15 June 2009 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
Alfonso SalvatoreAlfonso Salvatore
Alfonso Salvatore
LCLuisa Cigliano
Luisa Cigliano
ACAlessandro Carlucci
Alessandro Carlucci
EBEnrico M. Bucci
Enrico M. Bucci
PAPaolo Abrescia
Paolo Abrescia

1 December 2012 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Mariangela BiavaMariangela Biava
Mariangela Biava
CBClaudio Battilocchio
Claudio Battilocchio
GPGiovanna Poce
Giovanna Poce
Alfonso SalvatoreAlfonso Salvatore
Alfonso Salvatore
SCSara Consalvi
Sara Consalvi
MAMaurizio Anzini
Maurizio Anzini

27 November 2020 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Anna Maria PirasAnna Maria Piras
Anna Maria Piras
Ylenia ZambitoYlenia Zambito
Ylenia Zambito
MLMaurizio Lugli
Maurizio Lugli
BFBaldassare Ferro
Baldassare Ferro
PRPaolo Roncucci
Paolo Roncucci
RCRoberto Crea
Roberto Crea
The SARS-CoV-2 infection is associated with pulmonary coagulopathy, which determines the deposition of fibrin in the air spaces and lung parenchyma. The resulting lung lesions compromise patient pulmonary function and increase mortality, or end in permanent lung damage for those who have recovered from the COVID-19 disease. Therefore, local pulmonary fibrinolysis can be efficacious in degrading pre-existing fibrin clots and reducing the conversion of lung lesions into lasting scars. Plasminogen is considered a key player in fibrinolysis processes, and in view of a bench-to-bedside translation, we focused on the aerosolization of an orphan medicinal product (OMP) for ligneous conjunctivitis: human plasminogen (PLG-OMP) eye drops. As such, the sterile and preservative-free solution guarantees the pharmaceutical quality of GMP production and meets the Ph. Eur. requirements of liquid preparations for nebulization. PLG-OMP aerosolization was evaluated both from technological and stability viewpoints, after being submitted to either jet or ultrasonic nebulization. Jet nebulization resulted in a more efficient delivery of an aerosol suitable for pulmonary deposition. The biochemical investigation highlighted substantial protein integrity maintenance with the percentage of native plasminogen band > 90%, in accordance with the quality specifications of PLG-OMP. In a coherent way, the specific activity of plasminogen is maintained within the range 4.8–5.6 IU/mg (PLG-OMP pre-nebulization: 5.0 IU/mg). This is the first study that focuses on the technological and biochemical aspects of aerosolized plasminogen, which could affect both treatment efficacy and clinical dosage delivery. Increasing evidence for the need of local fibrinolytic therapy could merge with the availability of PLG-OMP as an easy handling solution, readily aerosolizable for a fast translation into an extended clinical efficacy assessment in COVID-19 patients.

30 May 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
LVLucia Vizzoni
Lucia Vizzoni
CMChiara Migone
Chiara Migone
BGBrunella Grassiri
Brunella Grassiri
Ylenia ZambitoYlenia Zambito
Ylenia Zambito
BFBaldassare Ferro
Baldassare Ferro
Anna Maria PirasAnna Maria Piras
Anna Maria Piras
Acute respiratory distress syndrome (ARDS) is a severe complication of lung injuries, commonly associated with bacterial, fungal and viral infections, including SARS-CoV-2 viral infections. ARDS is strongly correlated with patient mortality and its clinical management is very complex, with no effective treatment presently available. ARDS involves severe respiratory failure, fibrin deposition in both airways and lung parenchyma, with the development of an obstructing hyaline membrane drastically limiting gas exchange. Moreover, hypercoagulation is related to deep lung inflammation, and a pharmacological action toward both aspects is expected to be beneficial. Plasminogen (PLG) is a main component of the fibrinolytic system playing key roles in various inflammation regulatory processes. The inhalation of PLG has been proposed in the form of the off-label administration of an eyedrop solution, namely, a plasminogen-based orphan medicinal product (PLG-OMP), by means of jet nebulisation. Being a protein, PLG is susceptible to partial inactivation under jet nebulisation. The aim of the present work is to demonstrate the efficacy of the mesh nebulisation of PLG-OMP in an in vitro simulation of clinical off-label administration, considering both the enzymatic and immunomodulating activities of PLG. Biopharmaceutical aspects are also investigated to corroborate the feasibility of PLG-OMP administration by inhalation. The nebulisation of the solution was performed using an Aerogen® SoloTM vibrating-mesh nebuliser. Aerosolised PLG showed an optimal in vitro deposition profile, with 90% of the active ingredient impacting the lower portions of a glass impinger. The nebulised PLG remained in its monomeric form, with no alteration of glycoform composition and 94% of enzymatic activity maintenance. Activity loss was observed only when PLG-OMP nebulisation was performed under simulated clinical oxygen administration. In vitro investigations evidenced good penetration of aerosolised PLG through artificial airway mucus, as well as poor permeation across an Air–Liquid Interface model of pulmonary epithelium. The results suggest a good safety profile of inhalable PLG, excluding high systemic absorption but with good mucus diffusion. Most importantly, the aerosolised PLG was capable of reversing the effects of an LPS-activated macrophage RAW 264.7 cell line, demonstrating the immunomodulating activity of PLG in an already induced inflammatory state. All physical, biochemical and biopharmaceutical assessments of mesh aerosolised PLG-OMP provided evidence for its potential off-label administration as a treatment for ARDS patients.

14 July 2015 in Transfusion
Verified
Journal Article
Closed access
PDF file
Alfonso SalvatoreAlfonso Salvatore
Alfonso Salvatore
Semih EsinSemih Esin
Semih Esin
Giovanna BatoniGiovanna Batoni
Giovanna Batoni
EAEster Ascione
Ester Ascione
CFClaudio Farina
Claudio Farina
CNClaudia Nardini
Claudia Nardini